A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
NCT00162123
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
248
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Ipilimumab
Sponsor
Bristol-Myers Squibb